Inhibition of c-Kit is not required for reversal of hyperglycemia by imatinib in NOD mice

Recent studies indicate that tyrosine kinase inhibitors, including imatinib, can reverse hyperglycemia in non-obese diabetic (NOD) mice, a model of type 1 diabetes (T1D). Imatinib inhibits c-Abl, c-Kit, and PDGFRs. Next-generation tyrosine kinase inhibitors for T1D treatment should maintain activiti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2014-01, Vol.9 (1), p.e84900-e84900
Hauptverfasser:	Lau, Janet, Zhou, Qiang, Sutton, Susan E, Herman, Ann E, Schmedt, Christian, Glynne, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Animal experimentation Animal genetics Animals Antineoplastic agents Benzamides - therapeutic use Biology Blood Blood glucose c-Kit protein Cloning Diabetes Diabetes mellitus Disease Experiments Female Genomes Genomics Glucose Hematopoietic stem cells House mouse Hyperglycemia Hyperglycemia - drug therapy Hyperglycemia - physiopathology Imatinib Imatinib Mesylate Inhibition Inhibitor drugs Inhibitors Insulin Leukemia Medicine Mice Mice, Inbred NOD Mutation Obesity Patients Piperazines - therapeutic use Protein-tyrosine kinase Proto-Oncogene Proteins c-kit - antagonists & inhibitors Proto-Oncogene Proteins c-kit - genetics Proto-Oncogene Proteins c-kit - physiology Pyrimidines - therapeutic use Stem cell transplantation Stem cells Studies Type 2 diabetes Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!